Breast Ca Mortality Decline Greatest in Younger ER+ Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70

BETHESDA, Maryland—A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen-receptor (ER)-positive tumors and women younger than age 70 (J Clin Oncol published online April 2, 2007). Between 1990 and 2003, breast cancer mortality rates declined by 24%. The researchers found that among women under age 70, mortality declined 38% for those with ER-positive tumors vs 19% for ER-negative tumors, and among women 70 or older, by 14% for ER-positive tumors vs no decline for ER-negative tumors.

"These trends since 1990 are likely attributable to at least two factors: the use of tamoxifen after surgery . . . and widespread use of screening mammography, which is more likely to detect the slow-growing tumors that tend to be ER-positive," said lead author Ismail Jatoi, MD, PhD, of the Uniformed Services University of the Health Sciences.

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content